Shares of Natus Medical Inc. (NASDAQ:BABY) rose 2.5% during trading on Thursday . The company traded as high as $39.88 and last traded at $39.88, with a volume of 161,430 shares traded. The stock had previously closed at $38.91.

Separately, Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Thursday, July 7th.

The company’s 50-day moving average price is $39.04 and its 200-day moving average price is $36.13. The company has a market cap of $1.32 billion and a PE ratio of 35.03.

Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.03. The company earned $96 million during the quarter, compared to analyst estimates of $92.71 million. During the same period in the prior year, the business posted $0.34 earnings per share. Natus Medical’s revenue was up 4.5% on a year-over-year basis. On average, analysts predict that Natus Medical Inc. will post $1.68 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Natus Medical stock. Morgan Stanley raised its position in shares of Natus Medical Inc. (NASDAQ:BABY) by 108.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 242,583 shares of the company’s stock after buying an additional 125,964 shares during the period. Morgan Stanley owned about 0.75% of Natus Medical worth $11,656,000 at the end of the most recent reporting period.

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.